Reuters logo
BRIEF-Omeros reports more positive data in OMS721 phase 2 trial in renal diseases
March 30, 2017 / 11:21 AM / 6 months ago

BRIEF-Omeros reports more positive data in OMS721 phase 2 trial in renal diseases

March 30 (Reuters) - Omeros Corp

* Omeros reports more positive data in OMS721 phase 2 trial in renal diseases

* Phase 3 program slated for this year

* Consistent with all other OMS721 clinical trials, no significant safety concerns have been observed

* Preparing breakthrough application and phase 3 protocol for discussion with FDA; phase 3 trial in IGAN expected to begin this year

* New data corroborate and expand on trial results reported in Q4 of 2016 Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below